Drugs / ADAKITUG
ADAKITUG
also known as
BMS-986253 · HuMax IL8 · A33 124i · aIL8 · Anti-IL8 · BMS-986253-01 · Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) · Humax-inflam · +1 more
Monoclonal antibody targets CXCL8
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04572451 | Nov 2021 → May 2024 overdue | melanoma, refractory malignant neoplasm | Yana Najjar | Recruiting | No outcome recorded |
| Phase 1 | NCT02536469 | Aug 2015 → Nov 2016 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05148234 | Nov 2022 → Feb 2023 | myelodysplastic syndrome | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT03689699 | Oct 2018 → Sep 2023 overdue | prostate adenocarcinoma | Mark Stein | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03400332 | Feb 2018 → Apr 2024 | cancer, melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04848116 | Apr 2021 → Apr 2027 expected | head and neck squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04347226 | Apr 2020 → Mar 2021 | COVID-19, cancer, hematopoietic and lymphoid cell neoplasm | Columbia University | Terminated | No outcome recorded |
| Phase 2 | NCT04123379 | Mar 2020 → Aug 2023 | hepatocellular carcinoma, non-small cell lung carcinoma | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT04050462 | Sep 2019 → Jan 2025 | hepatocellular carcinoma | NYU Langone Health | Terminated | No outcome recorded |
| Phase 2 | NCT03026140 | Mar 2017 → Mar 2032 expected | colon carcinoma | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT02451982 | Mar 2016 → Sep 2026 expected | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05210894 Background | — | — | Bristol-Myers Squibb | No longer available | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADAKITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314551 ↗ |
| Known as | A33 124i | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314551 ↗ |
| Known as | aIL8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314551 ↗ |
| Known as | Anti-IL8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05210894 ↗ |
| Known as | BMS-986253 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02451982 ↗ |
| Known as | BMS-986253-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314551 ↗ |
| Known as | Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253) | “Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253)” NCT05148234 ↗ |
| Known as | HuMax IL8 | “BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8).” NCT03689699 ↗ |
| Known as | Humax-inflam | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314551 ↗ |
| Known as | MDX-018 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314551 ↗ |
| Action | Inhibit | “anti-IL8 antibody; HuMax-IL8” NCT02451982 ↗ |
| Modality | Monoclonal antibody | “anti-IL8 antibody; HuMax-IL8” NCT02451982 ↗ |
| Route | Intravenous | “2400 mg IV” NCT02451982 ↗ |
| Target | IL8 | “Human Humax (HuMax)-interleukin 8 (IL-8) (BMS-986253)” NCT05148234 ↗ |